Unknown

Dataset Information

0

Abscopal effect of stereotactic radiotherapy combined with anti-PD-1/PD-L1 immunotherapy: Mechanisms, clinical efficacy, and issues.

ABSTRACT:

SUBMITTER: Zhuang H 

PROVIDER: S-EPMC7743005 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Abscopal effect of stereotactic radiotherapy combined with anti-PD-1/PD-L1 immunotherapy: Mechanisms, clinical efficacy, and issues.

Zhuang Hongqing H  

Cancer communications (London, England) 20201110 12

Similar Datasets

Unknown Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers.
| S-EPMC8042160 | biostudies-literature
Unknown Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy.
| S-EPMC10587686 | biostudies-literature
Unknown Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect.
| S-EPMC12211843 | biostudies-literature
Unknown Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges.
| S-EPMC9883424 | biostudies-literature
Unknown PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
| S-EPMC4827718 | biostudies-literature
Unknown Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma.
| S-EPMC8170410 | biostudies-literature
Unknown The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy.
| S-EPMC12474601 | biostudies-literature
Unknown Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis.
| S-EPMC9174611 | biostudies-literature
Unknown Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
| S-EPMC10548684 | biostudies-literature
Unknown Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors.
| S-EPMC11705730 | biostudies-literature